Imsidolimab

FDA approved various treatments including Berdazimer Gel for Molluscum Contagiosum, Dupilumab for Atopic Dermatitis, Lifileucel for Melanoma, and others for conditions like Psoriasis, Rosacea, and Alopecia. Studies highlighted advancements in dermatology treatments and safety concerns over benzene in acne products.

AnaptysBio's ARISE-AD trial of BTLA agonist ANB032 for moderate-to-severe atopic dermatitis failed to meet primary and secondary endpoints, despite being well-tolerated. The trial involved 201 subjects globally, assessing safety, efficacy, and pharmacokinetics over 12 weeks. Subjects had a mean baseline EASI score of 27.3 and were administered ANB032 or placebo. Despite safety confirmation, ANB032 did not achieve a 75% EASI improvement or secondary endpoints. AnaptysBio will focus future efforts on other immunology therapeutics.

AnaptysBio's Q3 2024 10-Q report shows collaboration revenue up to $30.0M, with a net loss of $(32.9)M. The company advances its pipeline, including rosnilimab in Phase 2b for RA and UC, and ANB032 in Phase 2b for AD. Challenges include product development risks and regulatory approval hurdles.

Top-line Phase 2b data for ANB032 (BTLA agonist) in atopic dermatitis expected Dec 2024, rosnilimab (PD-1 agonist) in rheumatoid arthritis in Feb 2025. Phase 1 trial initiated for ANB033 (anti-CD122 antagonist). Cash runway reiterated through year-end 2026.

Hidradenitis suppurativa (HS) treatment insights highlight B cells, fibroblasts, and bacterial triggers as central to inflammation and fibrosis, with recent trials showing varying success rates for therapies targeting these elements, necessitating further research to understand HS pathogenesis and optimize treatment responses.